WO2005007149A8 - Ambroxol für die behandlung akuter schmerzen - Google Patents

Ambroxol für die behandlung akuter schmerzen

Info

Publication number
WO2005007149A8
WO2005007149A8 PCT/EP2004/007853 EP2004007853W WO2005007149A8 WO 2005007149 A8 WO2005007149 A8 WO 2005007149A8 EP 2004007853 W EP2004007853 W EP 2004007853W WO 2005007149 A8 WO2005007149 A8 WO 2005007149A8
Authority
WO
WIPO (PCT)
Prior art keywords
ambroxol
treating acute
acute pains
pains
treating
Prior art date
Application number
PCT/EP2004/007853
Other languages
English (en)
French (fr)
Other versions
WO2005007149A1 (de
Inventor
Thomas Weiser
Klaus Klinder
Wolfram Gaida
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Thomas Weiser
Klaus Klinder
Wolfram Gaida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Thomas Weiser, Klaus Klinder, Wolfram Gaida filed Critical Boehringer Ingelheim Int
Priority to JP2006519880A priority Critical patent/JP2009513551A/ja
Priority to CA002532309A priority patent/CA2532309A1/en
Priority to EP04741038A priority patent/EP1725225A1/de
Publication of WO2005007149A1 publication Critical patent/WO2005007149A1/de
Publication of WO2005007149A8 publication Critical patent/WO2005007149A8/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Ambroxol und dessen pharmakologisch verträglichen Salze zur Herstellung eines Arzneimittels zur Behandlung von akutem Schmerz.
PCT/EP2004/007853 2003-07-16 2004-07-15 Ambroxol für die behandlung akuter schmerzen WO2005007149A1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006519880A JP2009513551A (ja) 2003-07-16 2004-07-15 急性疼痛の治療のためのアンブロキソール
CA002532309A CA2532309A1 (en) 2003-07-16 2004-07-15 Ambroxol for treating acute pains
EP04741038A EP1725225A1 (de) 2003-07-16 2004-07-15 Ambroxol für die behandlung akuter schmerzen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10332486A DE10332486A1 (de) 2003-07-16 2003-07-16 Ambroxol für die Behandlung akuter Schmerzen
DE10332486.0 2003-07-16

Publications (2)

Publication Number Publication Date
WO2005007149A1 WO2005007149A1 (de) 2005-01-27
WO2005007149A8 true WO2005007149A8 (de) 2006-10-12

Family

ID=34041911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/007853 WO2005007149A1 (de) 2003-07-16 2004-07-15 Ambroxol für die behandlung akuter schmerzen

Country Status (6)

Country Link
US (2) US20050014844A1 (de)
EP (1) EP1725225A1 (de)
JP (1) JP2009513551A (de)
CA (1) CA2532309A1 (de)
DE (1) DE10332486A1 (de)
WO (1) WO2005007149A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
DE10332473A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Epilepsie
DE102004021992A1 (de) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topische Zubereitung enthaltend Ambroxol
US20090143415A1 (en) * 2004-09-21 2009-06-04 Wex Pharmaceuticals, Inc. Tetrodotoxin And Its Derivatives For The Treatment Of Central-Nervously Derived Neuropathic Pain
JP2008513528A (ja) * 2004-09-22 2008-05-01 ウェックス ファーマシューティカルズ インコーポレイテッド 末梢神経由来の神経障害性疼痛の治療用テトロドトキシンおよびその誘導体
EP1714655A1 (de) * 2005-04-22 2006-10-25 Laboratorios Del Dr. Esteve, S.A. Verwendung eines Natriumkanalblockers und deren Analoga zur Behandlung von Nikotinabhängigkeit
EP1928452A4 (de) * 2005-08-25 2010-09-01 Wex Medical Ltd Verwendung von natriumkanalblockern zur behanldung von viszeralen schmerzen oder schmerzen durch krebsbehandlung
US20100048592A1 (en) * 2005-08-25 2010-02-25 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the management of musculoskeletal pain
CN101563079B (zh) * 2006-03-27 2012-12-05 威克斯药业有限公司 钠通道阻滞剂在制备治疗由于化疗而产生的神经病理性疼痛的药物中的用途
EA201300535A1 (ru) 2010-12-23 2013-08-30 Лектио Фармаэнтвиклунгс - Унд Фервертунгс Гмбх Водный раствор амброксола
US10702485B2 (en) * 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
WO2015102719A2 (en) * 2013-10-15 2015-07-09 United Technologies Corporation Non-linear bumper bearings
US20150190377A1 (en) * 2014-01-06 2015-07-09 The Regents Of The University Of California, A California Corporation Neuronal regeneration
JP6871400B2 (ja) 2016-11-14 2021-05-12 ミングゥ・ワン 眼表面疾患の治療のための製剤および関連方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568358A (en) * 1896-09-29 Paper-pulp engine
ATE140213T1 (de) * 1990-03-08 1996-07-15 Fujisawa Pharmaceutical Co N-monosubstituierte cyclopentenylamine, ein verfahren zu ihrer herstellung, und ihre verwendung als medikament
CA2038597A1 (en) * 1991-03-19 1992-09-20 Jose P. Garzaran A method and a pharmaceutical preparation for treating pain
US5612061A (en) * 1994-10-14 1997-03-18 Rabkin; Simon W. Composition and method for the treatment of premenstrual syndrome
AU5347996A (en) * 1995-04-26 1996-11-18 Taisho Pharmaceutical Co., Ltd. Preparation for oral administration
US6518311B2 (en) * 1997-07-09 2003-02-11 D-Pharm Ltd. Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US20020009478A1 (en) * 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
JP2000080034A (ja) * 1998-09-02 2000-03-21 Taisho Pharmaceut Co Ltd 風邪用組成物
JP2001151677A (ja) * 1999-11-26 2001-06-05 Taisho Pharmaceut Co Ltd 咽頭用組成物
GB0128674D0 (en) * 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
DE10203104A1 (de) * 2002-01-25 2003-08-07 Boehringer Ingelheim Pharma Ambroxol für die Behandlung chronischer Schmerzen
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
DE10208313A1 (de) * 2002-02-27 2003-09-11 Boehringer Ingelheim Pharma Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum
EP1417961A1 (de) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Neue pharmazeutische Zubereitung enthaltend eine Kombination von Ambroxol oder Bromhexin und Isopropamid Jodid
DE10332473A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Epilepsie
DE10332487A1 (de) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen

Also Published As

Publication number Publication date
JP2009513551A (ja) 2009-04-02
US20080009548A1 (en) 2008-01-10
CA2532309A1 (en) 2005-01-27
EP1725225A1 (de) 2006-11-29
DE10332486A1 (de) 2005-02-10
WO2005007149A1 (de) 2005-01-27
US20050014844A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
AU2003300791A1 (en) Combination therapy for the treatment of pain
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
AU2003286567A1 (en) Methods for the treatment of skin disorders
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
PL373568A1 (en) Use of i kappa b kinase inhibitors for the treatment of pain
EP1581629A4 (de) Verfahren zur identifizierung,beurteilung und behandlung von patienten mit einerproteasomeninhibitionstherapie
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
WO2005007149A8 (de) Ambroxol für die behandlung akuter schmerzen
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
HK1051690A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamidederivatives for the treatment of pain.
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
HK1075843A1 (en) 1-phenyl-2-dimethylaminomethyl cyclohexane compounds used for the therapy of depressive symptoms, pain, and incontinence
AU2003263628A1 (en) Medical treatment system for stimulating spots on the body suitable for acupuncture
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
ZA200107143B (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders.
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
WO2002083083A3 (en) Pharmaceutically active compounds and methods of use
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
IL155431A0 (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
AU2003294941A1 (en) Combinations of a vanilloid antagonist and an nsaid for the treatment of pain
MXPA02009434A (es) Formulacion medicinal para la estimulacion de la leucopoyesis para el tratamiento de enfermedades tumorales y de protozoos, de acarinosis, artropodiasis y un procedimiento para su preparacion.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004741038

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2532309

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006519880

Country of ref document: JP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 04/2005 UNDER (71 AND 81) REPLACE "WRONG PUBLISHED DESIGNATIONS" BY "CORRECT DESIGNATIONS"; DUE TO A TRANSFER PROBLEM BY THE PUBLICATION

WWP Wipo information: published in national office

Ref document number: 2004741038

Country of ref document: EP